6308 completed, 1881 recruiting, 1688 unknown, 803 terminated. 4291 Not applicable, 2321 Phase 2, 1576 Phase 1, 1077 Phase 3, 397 Phase 4.
Follow Neurodegenerative Diseases: new trials by email Literature Review of Neurodegenerative Diseases trials Research Report on Neurodegenerative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tau Pathology in the Brain After Hip or Knee Replacement Surgery Hip or Knee Arthroplasty Under Spinal Anesthesia - Postoperative Cognitive Dysfunction, Alzheimer Disease | Recruiting | Uppsala University Hospital | 30 | 2029-04-01 | 2026-10-15 | |
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy | Phase 1 | Not yet recruiting | Guangzhou Magpie Pharmaceuticals Co., Ltd. | 16 | 2028-09-01 | 2026-09-11 |
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Smartphone App for Adolescents With Idiopathic Scoliosis DinSkoliose smartphone application - Adolescence Idiopathic Scoliosis, AIS | Not applicable | Not yet recruiting | Oslo Metropolitan University | 30 | 2028-04-01 | 2026-07-07 |
| Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease active subthalamic nucleus deep brain stimulation plus optimal drug therapy, inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy - Parkinson Disease | Not applicable | Not yet recruiting | Mallory Hacker | 40 | 2028-01-01 | 2026-02-20 |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Transcranial Magnetic Stimulation for Alzheimer's Disease Treatment Active Transcranial Magnetic Stimulation, Sham Transcranial Magnetic Stimulation - Alzheimer Disease | Not applicable | Not yet recruiting | Universitat Oberta de Catalunya | 45 | 2027-11-01 | 2026-07-21 |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Not yet recruiting | Institute for Molecular Medicine | 160 | 2027-10-01 | 2026-10-21 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS) B cell infusion - ALS - Amyotrophic Lateral Sclerosis | Phase 1 | Not yet recruiting | Mark Poznansky | 10 | 2027-09-01 | 2026-09-24 |
| Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) rTMS - Parkinson Disease | Not applicable | Not yet recruiting | University of Michigan | 20 | 2027-09-01 | 2026-10-20 |
| Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents - Alzheimer Disease, Early Onset | Phase 1 | Not yet recruiting | Columbia University | 6 | 2027-08-01 | 2026-05-13 |
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) GV1001 Placebo, GV1001 1.12mg - Moderate to Severe Alzheimer's Disease | Phase 3 | Not yet recruiting | Samsung Pharmaceutical Co., Ltd. | 750 | 2027-07-01 | 2026-06-10 |
| Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics Levodopa (L-dopa) - Parkinson's Disease | Phase 4 | Not yet recruiting | Beth Israel Deaconess Medical Center | 40 | 2027-07-01 | 2026-08-28 |
| Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease Fecal Microbiota Transplant - Parkinson Disease | Phase 1 | Not yet recruiting | ProgenaBiome | 10 | 2027-07-01 | 2026-10-09 |
| Engage-PD: a Physical Activity Coaching Program Via Telehealth for People With Parkinson's Disease. A Single-cohort Study in Spain. Physical Activity Coaching - PARKINSON DISEASE (Disorder) | Not applicable | Not yet recruiting | Hospital Clinic of Barcelona | 30 | 2027-06-01 | 2026-10-05 |
| Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A | Phase 1 / Phase 2 | Withdrawn | Nationwide Children's Hospital | 2027-04-01 | 2026-07-29 | |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
Showing 20 of 12359. Sign in to see all of them.
Parkinson Disease (4476) · Alzheimer Disease (3878) · Dementia (1050) · Cognitive Dysfunction (974) · Amyotrophic Lateral Sclerosis (973) · Myasthenia Gravis (319) · Huntington Disease (292) · Muscular Atrophy, Spinal (279) · Motor Activity (278) · Lewy Body Disease (236) · Tourette Syndrome (233) · Frontotemporal Dementia (205) · Nervous System Diseases (205) · Movement Disorders (204)
Nervous System Diseases (12154) · Central Nervous System Diseases (10781) · Brain Diseases (9508) · Basal Ganglia Diseases (5383) · Movement Disorders (5247) · Mental Disorders (5000) · Synucleinopathies (4715) · Neurocognitive Disorders (4518) · Parkinsonian Disorders (4479) · Tauopathies (3970) · Dementia (3429) · Neuromuscular Diseases (2456) · Pathological Conditions, Signs and Symptoms (2269) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2265)
Donepezil (143) · Exercise (136) · Transcranial Direct Current Stimulation (110) · Deep Brain Stimulation (102) · Transcranial Magnetic Stimulation (97) · Levodopa (91) · Blood Specimen Collection (88) · carbidopa, levodopa drug combination (75) · Memantine (65) · Magnetic Resonance Spectroscopy (63) · florbetapir (60) · rasagiline (52) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (51) · Pramipexole (46) · rotigotine (46)
National Institute of Neurological Disorders and Stroke (NINDS) (130) · Assistance Publique - Hôpitaux de Paris (124) · Massachusetts General Hospital (98) · Pfizer (94) · Novartis Pharmaceuticals (83) · Johns Hopkins University (82) · Washington University School of Medicine (77) · Biogen (70) · University of Florida (70) · Eli Lilly and Company (67) · NYU Langone Health (67) · University Hospital, Toulouse (67) · VA Office of Research and Development (65) · Mayo Clinic (63) · University of Minnesota (62)
United States (5358) · France (1452) · Italy (979) · Canada (950) · United Kingdom (903) · Germany (876) · China (840) · Spain (805) · Netherlands (472) · Australia (420) · Belgium (375) · Japan (358) · Poland (357) · South Korea (348) · Taiwan (324)
PMID 36602886, PMID 38588457, PMID 39498781, PMID 33189083, PMID 40603145, PMID 40680102, PMID 39800465, PMID 31420846, PMID 31356217, PMID 34383289, PMID 36463457, PMID 33974419, PMID 34815790, PMID 36449262, PMID 37148485, PMID 38489195, PMID 40049590, PMID 41224659, PMID 25623333, PMID 25918556, PMID 26120369, PMID 26402769, PMID 29480210, PMID 30741694, PMID 30936738, PMID 31127735, PMID 32250312, PMID 33417236, PMID 34108929, PMID 37171121, PMID 38058356, PMID 39324520, PMID 40368603, PMID 40667684, PMID 40681915, PMID 40739200, PMID 41533472, PMID 41804324, PMID 41961243, PMID 10816186, PMID 15817019, PMID 16267188, PMID 19126811, PMID 23300829, PMID 25803389, PMID 26554876, PMID 27538531, PMID 27807285, PMID 27871675, PMID 27939059
2023 (81), 2025 (64), 2017 (50), 2016 (48), 2018 (44), 2019 (40), 2015 (38), 2014 (37), 2009 (31), 2008 (18), U54AG063546 (9), 2004 (8), 2005 (6), U01AG010483 (6), P30AG024978 (5)